article thumbnail

ECDC and EMA highlight considerations for additional and booster doses.

The Pharma Data

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC). EMA will also be assessing data on booster doses. Source link : [link].

article thumbnail

Health Care Workers, Nursing Home Residents to Get First Vaccines: Panel

The Pharma Data

1, 2020 — Health care workers and people in nursing homes should be at the front of the line for upcoming COVID-19 vaccines, a U.S. Centers for Disease Control and Prevention advisory panel recommended Tuesday. The logic is that health care workers are crucial to keeping overtaxed U.S. health care systems working.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Keys to Success in Vaccine Development for Special Populations

PPD

Children and the elderly are among the most vulnerable populations and must be given special consideration in vaccine clinical trials to ensure their protection against vaccine-treatable diseases. The Many Considerations of Pediatric Vaccine Clinical Trials Childhood vaccines are highly effective in the prevention of many diseases.

Vaccine 52
article thumbnail

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

BioNTech plans to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccines, antibody and cell and gene therapy candidates to support the development of its diversified cancer and infectious disease product pipeline.

Vaccine 52
article thumbnail

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

million shots have now been administered in long-term care facilities, according to the U.S. Centers for Disease Control and Prevention. . “That combination really does make me think this is not just broad national patterns, but that vaccines probably are playing a role,” Dr. Jha said.

Nurses 52
article thumbnail

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. It is being administered together with FOLFOX chemotherapy.

article thumbnail

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

We await results from PROVENT, our pre-exposure prevention trial and TACKLE, our treatment trial in preventing more severe disease, to understand the potential role of AZD7442 in protecting against COVID-19.”. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.

Trials 52